Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Mat D. Davis · SciRah

Researcher profile · Semantic Scholar

Mat D. Davis

Share profile

Mat D. Davis — researcher profile on SciRah

h-index: 11
Works: 38
Citations: 907

Most-cited papers

Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline
P. Doraiswamy, R. Sperling, R. Coleman, Keith A. Johnson +12 more
2012Neurology208 citations Open access
Semantic Scholar
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
K. E. Anderson, D. Stamler, Mat D. Davis, S. Factor +9 more
2017Lancet psychiatry158 citations
Semantic Scholar
Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals
R. Sperling, Keith A. Johnson, P. Doraiswamy, E. Reiman +13 more
2012Neurobiology of Aging136 citations Open access
Semantic Scholar
Randomized controlled trial of deutetrabenazine for tardive dyskinesia
Hubert H. Fernandez, S. Factor, Robert A. Hauser, J. Jimenez-shahed +11 more
2017Neurology99 citations Open access
Semantic Scholar
Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo‐controlled trial
D. Weintraub, R. Hauser, J. Elm, F. Pagán +2 more
2016Movement Disorders70 citations
Semantic Scholar
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability
N. Larocca, Lynn D. Hudson, R. Rudick, D. Amtmann +34 more
2017Multiple Sclerosis60 citations Open access
Semantic Scholar
Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia
H. Fernandez, D. Stamler, Mat D. Davis, S. Factor +9 more
2019Journal of Neurology Neurosurgery & Psychiatry48 citations Open access
Semantic Scholar
Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing–remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study
O. Khan, P. Rieckmann, A. Boyko, K. Selmaj +4 more
2017Multiple Sclerosis33 citations Open access
Semantic Scholar
Increased Risk of New-Onset Hypertension in Patients With Narcolepsy Initiating Sodium Oxybate: A Real-World Study.
Rami H. Ben-Joseph, V. Somers, Jed Black, Ralph B. D'Agostino +7 more
2024Mayo Clinic proceedings19 citations Open access
Semantic Scholar
Comparative utility of disability progression measures in PPMS
M. Koch, G. Cutter, G. Giovannoni, B. Uitdehaag +4 more
2017Neurology: Neuroimmunology & Neuroinflammation16 citations Open access
Semantic Scholar
Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study
Mat D. Davis, N. Ashtamker, J. Steinerman, V. Knappertz
2017Neurology: Neuroimmunology & Neuroinflammation12 citations Open access
Semantic Scholar
The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing‐Remitting Multiple Sclerosis
R. Zivadinov, M. Dwyer, D. Ramasamy, Mat D. Davis +2 more
2015Journal of Neuroimaging6 citations Open access
Semantic Scholar
Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study
P. Rieckmann, R. Zivadinov, A. Boyko, K. Selmaj +8 more
2021Multiple Sclerosis Journal - Experimental, Translational and Clinical5 citations Open access
Semantic Scholar
BEHAVIORAL AND TRANSCRIPTOMIC EFFECTS OF A NOVEL CANNABINOID ON A RAT VALPROIC ACID MODEL OF AUTISM.
Sally Loomis, D. Silva, Ranjev Savopoulos, Jackie Cilia +6 more
2025Neuropharmacology4 citations Open access
Semantic Scholar
Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Effect of Fixed-Dose Deutetrabenazine by Baseline Comorbidities (S56.006)
K. Anderson, S. Factor, Mat D. Davis, R. Hauser +5 more
2017Neurology4 citations
Semantic Scholar
Deutetrabenazine Treatment Response by Concomitant Dopamine-Receptor Antagonists in the Phase III, Randomized, Double-Blind, Placebo-Controlled AIM-TD Trial in Tardive Dyskinesia (TD) (P2.016)
J. Jimenez-shahed, H. Fernandez, D. Stamler, Mat D. Davis +5 more
2017Neurology4 citations
Semantic Scholar
Efficacy and safety of a three-times weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study (P7.273)
O. Khan, P. Rieckmann, A. Boyko, K. Selmaj +4 more
2015Neurology3 citations
Semantic Scholar
45 Long-term Treatment with Deutetrabenazine Is Associated with Continued Improvement in Tardive Dyskinesia: Results from an Open-label Extension Study
Robert A. Hauser, Hubert H. Fernandez, D. Stamler, Mat D. Davis +8 more
2019CNS Spectrums2 citations Open access
Semantic Scholar
46 Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-label Extension Study
Hubert H. Fernandez, D. Stamler, Mat D. Davis, S. Factor +8 more
2019CNS Spectrums2 citations Open access
Semantic Scholar
134 Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD and AIM-TD Studies
H. Fernandez, Mat D. Davis, S. Factor, R. Hauser +6 more
2018CNS Spectrums2 citations Open access
Semantic Scholar
Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Efficacy, Safety, and Tolerability of Fixed-Dose Deutetrabenazine for the Treatment of Moderate to Severe Tardive Dyskinesia (TD) (S56.007)
K. Anderson, D. Stamler, Mat D. Davis, S. Factor +5 more
2017Neurology2 citations
Semantic Scholar
Increased Risk of Hypertension Onset Among Patients With Narcolepsy Newly Treated With High-Sodium Oxybate (P5-13.002)
R. Ben-Joseph, V. Somers, J. Black, Ralph B. D'Agostino +11 more
2023Monday, April 241 citations
Semantic Scholar
Long-Term Efficacy and Safety of Deutetrabenazine for Chorea in Huntington's Disease: Results From the ARC-HD Open-label Study.
S. Frank, C. Testa, D. Stamler, E. Kayson +7 more
2021CNS Spectrums1 citations Open access
Semantic Scholar
Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington’s Disease (4310)
Samuel Frank, Christina L. Vaughan, D. Stamler, David Oakes +10 more
2020Neurology1 citations
Semantic Scholar
34 Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline Comorbidities
K. E. Anderson, D. Stamler, Mat D. Davis, Robert A. Hauser +6 more
2019CNS Spectrums1 citations Open access
Semantic Scholar
Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-Label Extension Study (P4.075)
Hubert H. Fernandez, D. Stamler, Mat D. Davis, S. Factor +8 more
2018Neurology1 citations
Semantic Scholar
Deutetrabenazine is Associated with an Improvement in Involuntary Movements in Patients With Tardive Dyskinesia (TD) as Seen by the High Proportion of Responders to Deutetrabenazine Treatment in the AIM-TD Study (P2.020)
J. Jimenez-shahed, Hubert H. Fernandez, D. Stamler, Mat D. Davis +5 more
2017Neurology1 citations
Semantic Scholar
Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Improvements in Clinical Global Impression of Change (CGIC) with Deutetrabenazine Treatment in Moderate to Severe Tardive Dyskinesia (TD) (S56.004)
H. Fernandez, R. Hauser, Mat D. Davis, S. Factor +5 more
2017Neurology1 citations
Semantic Scholar
Long-Term Follow-Up of Laquinimod 0.6 mg in Patients with Relapsing-Remitting Multiple Sclerosis 2 (P3.087)
G. Comi, T. Vollmer, F. Lublin, Yuval Dadon +4 more
2016Neurology1 citations
Semantic Scholar
Efficacy of rasagiline in PD patients with mild cognitive impairment
D. Weintraub, R. Hauser, Mat D. Davis, A. Choudhry
20161 citations
Semantic Scholar
Time Course of Glatiramer Acetate Efficacy in Relapsing-Remitting Multiple Sclerosis Patients in the Glatiramer Acetate Low-Frequency Administration (GALA) Study (S51.006)
Mat D. Davis, N. Ashtamker, J. Steinerman, V. Knappertz
2016Neurology1 citations
Semantic Scholar
MRI indicators of brain tissue loss: 3-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study in relapsing-remitting multiple sclerosis (P7.255)
R. Zivadinov, M. Dwyer, N. Bergsland, D. Ramasamy +4 more
2015Neurology1 citations
Semantic Scholar
Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington's Disease.
S. Frank, C. Vaughan, D. Stamler, D. Oakes +10 more
2021CNS Spectrums0 citations Open access
Semantic Scholar
35 Long-term Improvements in Site-Rated Outcomes with Deutetrabenazine Treatment in Patients with Tardive Dyskinesia
K. E. Anderson, D. Stamler, Mat D. Davis, Nicholas Gross +7 more
2019CNS Spectrums0 citations Open access
Semantic Scholar
158 Long-Term Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study
K. Anderson, Mat D. Davis, S. Factor, R. Hauser +6 more
2018CNS Spectrums0 citations Open access
Semantic Scholar
Long-Term Treatment With Deutetrabenazine is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study (P4.076)
R. Hauser, Hubert H. Fernandez, D. Stamler, Mat D. Davis +8 more
2018Neurology0 citations
Semantic Scholar
149 Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study
K. Anderson, Mat D. Davis, S. Factor, R. Hauser +7 more
2018CNS Spectrums0 citations Open access
Semantic Scholar
Predictors of Disability in Relapsing-Remitting Multiple Sclerosis (RRMS) During the Glatiramer Acetate Low-frequency Administration (GALA) Study (P6.357)
J. Alexander, Donald R. Daudt, Mat D. Davis, N. Ashtamker +1 more
2017Neurology0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Stamler×17
Invite
D. Stamler — researcher profile on SciRah
J. Jimenez-shahed×17
Invite
J. Jimenez-shahed — researcher profile on SciRah
S. Factor×14
Invite
S. Factor — researcher profile on SciRah
L. F. Jarskog×12
Invite
L. F. Jarskog — researcher profile on SciRah

×9

Invite

K. E. Anderson — researcher profile on SciRah

Hubert H. Fernandez×9

Invite

Hubert H. Fernandez — researcher profile on SciRah

Invite

R. Hauser — researcher profile on SciRah

H. Fernandez×8

Invite

H. Fernandez — researcher profile on SciRah

Invite

W. Ondo — researcher profile on SciRah

Invite

K. Anderson — researcher profile on SciRah

Invite

S. Ochudło — researcher profile on SciRah

Robert A. Hauser×6

Invite

Robert A. Hauser — researcher profile on SciRah